Impact of Acquired FXIII Deficiency on Morbidity and Mortality

Impact of Acquired FXIII Deficiency on Morbidity and Mortality Among Hospitalized Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04416594

Enrollment

Registered

2020-06-04

Start date

2019-09-10

Completion date

2020-05-18

Last updated

2020-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acquired Factor XIII Deficiency Disease

Keywords

Factor XIII, Blood transfusion, Mortality

Brief summary

Observational prospective study aiming to assess acquired FXIII deficiency implications in morbidity and mortality

Detailed description

All patients admitted to a large tertiary hospital with FXIII levels below 70% during their hospital stay are assessed. Data regarding patient background, blood transfusion, morbidity and mortality is registered.

Interventions

OTHERData collection

Only data collection

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* FXIII levels \< 70%

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame	Description
Cut-Point levels of FXIII	2 years	The investigators aim to find a laboratory parameter, a cut-point plasma level of FXIII, to identify an increased in morbidity and mortality in a mixed cohort of hospitalized patients

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026